Retail pharmacy sales on the rise

December 1, 1997

Pharmaceutical Representative

The market for retail pharmacy sales rose 15.8% during the second quarter, according to Newton, PA-based Scott-Levin. In its "Source Prescription Audit," the company reported that pharmaceutical companies generated a total of $20.7 billion during the quarter.

The market for retail pharmacy sales rose 15.8% during the second quarter, according to Newton, PA-based Scott-Levin. In its "Source Prescription Audit," the company reported that pharmaceutical companies generated a total of $20.7 billion during the quarter.

Driven by the success of Imitrex, Flonase, Epivir and Serevent, Glaxo Wellcome was responsible for the largest portion (6.7%) of retail pharmacy sales. Merck added the second largest share (6.5%) with Aocor, Fosamax, Cozaar and Hyzaar. Pfizer contributed the third largest sales (6.2%) with strong performances by Norvasc, Cardura, Zithromax and Zyrtec.

American Home Products and Bristol-Myers Squibb rounded out the top five in second-quarter sales with 6% and 5.7%, respectively.

Four of the top 10 corporations increased their U.S. retail pharmacy dollars by more than 20%: Eli Lilly and SmithKline Beecham raised their revenues by 21%; Bristol-Myers Squibb improved its stance by 24%; and Schering-Plough boosted its sales by 32%. PR

Related Content:

News